GLPG Galapagos NV

160.24
+2.13  (+1%)
Previous Close 158.11
Open 159.35
Price To Book 7.75
Market Cap 9,879,130,261
Shares 61,652,086
Volume 18,338
Short Ratio
Av. Daily Volume 201,615

NewsSee all news

  1. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  2. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  3. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

  4. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data lower than expectations released June 28, 2018.
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 trial initiation announced July 5, 2017.
Filgotinib
Non-infectious uveitis
Phase 2b data due 2H 2020.
GLPG1972 - ROCCELLA
Osteoarthritis
Phase 2 data due 3Q 2019.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 initiated August 2016
Filgotinib - FINCH 4
Rheumatoid arthritis (RA)
Phase 3 data released March 28, 2019 - primary endpoint met.
Filgotinib - FINCH 3
Rheumatoid arthritis (RA)
Phase 3 data released September 11, 2018. Endpoints met.
Filgotinib - FINCH 2
Rheumatoid arthritis (RA)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib - EQUATOR
Psoriatic arthritis
Phase 2a postive top-line data released November 20, 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 3 trial initiation announced December 17, 2018.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 enrolment to be completed 3Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing due 3Q 2019.
Filgotinib
Rheumatoid arthritis (RA)
Phase 2 trial to be completed 2019/20
MOR106 IGUANA
Atopic dermatitis
Phase 2 enrolment to be completed in 2019.
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2 initiation announced January 7, 2019.
GLPG1690 - NOVESA
Systemic sclerosis
Phase 2 initiation announced April 23, 2019.
MOR106 GECKO
Atopic dermatitis
Phase 1 data due 2H 2019.
GLPG3312
Healthy volunteers

Latest News

  1. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  2. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  3. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

  4. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian